Ignite Creation Date:
2024-05-06 @ 8:11 AM
Last Modification Date:
2024-10-26 @ 11:57 AM
Study NCT ID:
NCT02688270
Status:
COMPLETED
Last Update Posted:
2022-11-02
First Post:
2016-02-18
Brief Title:
Efficacy and Safety of Vascana in Subjects With Secondary Raynauds Phenomenon
Sponsor:
Covis Pharma Sàrl
Organization:
Covis Pharma Sàrl
Study Overview
Official Title:
A Double-blinded Crossover Study of Topical Formulation of Nitroglycerine Vascana Versus Matching Vehicle in the Subjective and Physiologic Responses to Controlled Cold Challenge in Subjects With Raynauds Phenomenon RP Secondary to Connective Tissue Disease
Status:
COMPLETED
Status Verified Date:
2022-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the ability of Vascana 09 nitroglycerin topical cream to treat and prevent the symptoms experienced by subjects with Raynauds Phenomenon The symptoms of this disease include pain tingling and numbness in the fingers of the affected hand or hands
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None